Dyadic International Inc (NASDAQ:DYAI) is a multinational biotech company and is best known for its C1-cell protein production platform. While it is true that the stock has been trading in a range, it is necessary to note that the platform is a product that not only speeds up development but also cuts down on production costs of biologic vaccines.
The platform also offers considerable flexibility when it comes to commercial scales when it comes to production. Over the past few trading sessions, the Dyadic stock has been trading within a range but the company’s work with its proprietary platform makes it a stock that could be worth keeping in the watch lists.
Trading Data
On Thursday, DYAI stock fell marginally to close at $4.22 with more than 69k shares, compared to its average volume of 2.25 million shares. The stock moved within a range of $4.1800 – 4.3600 after opening the trade at $4.28.
To Report Q3 Earnings Next Week
Last month the company had announced that it was going to announce its financial results for the third fiscal quarter that had ended on September 30, 2021 on November 10, 2021. Hence, it could be argued that in the lead up to that day, the stock could come into focus among investors.
Investors need to also note that the management at Dyadic will also host a conference in relation to its financial results on the same day. The conference call will begin at 5 p.m. Eastern Time and will provide a deeper look into the performance.
Technical Data
DYAI stock has gained almost 18% over the past 3-Month. The stock has RSI of 35 – signalling a potential bounce back from the oversold zone. Moreover, the stock is trading just 7% away from its 20-Day moving average.
